Can we differentiate among newer agents for MRSA bacteremia and endocarditis?

Let's Talk MRSA: 20 Frequently Asked Questions
09/01/2011

Listen "Can we differentiate among newer agents for MRSA bacteremia and endocarditis?"

Descargar episodio Ver en sitio original

Episode Synopsis


In this Episode, Dr. James S. Lewis from University of Texas Health Sciences Center in San Antonio,
Texas provides insights on differentiation among newer agents for MRSA bacteremia and endocarditis.

More episodes of the podcast Let's Talk MRSA: 20 Frequently Asked Questions

What are the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections? 13/02/2011
How can we prevent the spread of MRSA in the hospital? 06/02/2011
Is there a role for OPAT in the management of patients with MRSA infections? 30/01/2011
Can we determine the appropriate duration of therapy for MRSA infections? 23/01/2011
What stewardship tactics can be applied to the management of MRSA infections? 16/01/2011
How should clinicians manage MRSA bacteremia and infective endocarditis? 02/01/2011
How can primary care physicians manage community-associated MRSA pneumonia? 26/12/2010
What is the optimal treatment for MRSA nosocomial pneumonia? 19/12/2010
What are the therapeutic options for a complicated skin or skin structure MRSA infection? 12/12/2010
How can clinicians optimally manage community-associated MRSA skin infections? 05/12/2010
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA